Image via Wikipedia This stock has been on my radar for a couple of months. Arqule could be the next Dendreon. It is a cash cow and needs a little more clinical trial data before I pull the trigger but I will continue to watch this stock. I will keep you up to date if anything changes. Currently AQ197 is entering Phase III clinical trials for non-small cell lung cancer with Japanese partner Daiichi Sankyo.ArQule: (ARQL)
Daiichi Sankyo: (Tokyo: 4568)
ArQule's sky-high, but there still could be upside
By Val Brickates Kennedy, MarketWatch June 4, 2010
